261 related articles for article (PubMed ID: 21150564)
1. Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy.
Hallemeier CL; Botros M; Corsini MM; Haddock MG; Gunderson LL; Miller RC
Am J Clin Oncol; 2011 Dec; 34(6):567-72. PubMed ID: 21150564
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005).
Corsini MM; Miller RC; Haddock MG; Donohue JH; Farnell MB; Nagorney DM; Jatoi A; McWilliams RR; Kim GP; Bhatia S; Iott MJ; Gunderson LL
J Clin Oncol; 2008 Jul; 26(21):3511-6. PubMed ID: 18640932
[TBL] [Abstract][Full Text] [Related]
3. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
[TBL] [Abstract][Full Text] [Related]
4. Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinoma.
Moghanaki D; Mick R; Furth EE; Sohal D; Salmon PM; Behbahani A; Morgans AK; Miller SM; Giantonio BJ; Whittington RW; Haller DG; Rosato EF; Plastaras JP
JOP; 2011 Sep; 12(5):438-44. PubMed ID: 21904068
[TBL] [Abstract][Full Text] [Related]
5. Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma.
Yang R; Cheung MC; Byrne MM; Jin X; Montero AJ; Jones C; Koniaris LG
Arch Surg; 2010 Jan; 145(1):49-56. PubMed ID: 20083754
[TBL] [Abstract][Full Text] [Related]
6. Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.
Miller RC; Iott MJ; Corsini MM
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):364-8. PubMed ID: 19735864
[TBL] [Abstract][Full Text] [Related]
7. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma.
Malaisrie SC; Hofstetter WL; Correa AM; Ajani JA; Komaki RR; Rice DC; Vaporciyan AA; Walsh GL; Roth JA; Wu TT; Swisher SG
Cancer; 2006 Sep; 107(5):967-74. PubMed ID: 16874819
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?
Schnelldorfer T; Ware AL; Sarr MG; Smyrk TC; Zhang L; Qin R; Gullerud RE; Donohue JH; Nagorney DM; Farnell MB
Ann Surg; 2008 Mar; 247(3):456-62. PubMed ID: 18376190
[TBL] [Abstract][Full Text] [Related]
9. Preoperative versus postoperative chemoradiation for patients with resected pancreatic adenocarcinoma.
Pendurthi TK; Hoffman JP; Ross E; Johnson DE; Eisenberg BL
Am Surg; 1998 Jul; 64(7):686-92. PubMed ID: 9655283
[TBL] [Abstract][Full Text] [Related]
10. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
[TBL] [Abstract][Full Text] [Related]
11. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
[TBL] [Abstract][Full Text] [Related]
12. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade.
Wheeler JM; Dodds E; Warren BF; Cunningham C; George BD; Jones AC; Mortensen NJ
Dis Colon Rectum; 2004 Dec; 47(12):2025-31. PubMed ID: 15657650
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience.
Gold DG; Miller RC; Haddock MG; Gunderson LL; Quevedo F; Donohue JH; Bhatia S; Nagorney DM
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):150-5. PubMed ID: 19297105
[TBL] [Abstract][Full Text] [Related]
14. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
15. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer.
Kang CM; Kim JY; Choi GH; Kim KS; Choi JS; Lee WJ; Kim BR
J Surg Res; 2007 Jun; 140(1):31-5. PubMed ID: 17418869
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: role of CEA and CA 19-9.
Weissenberger C; Von Plehn G; Otto F; Barke A; Momm F; Geissler M
Anticancer Res; 2005; 25(3A):1787-93. PubMed ID: 16033101
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
18. Significance of pathologic response to preoperative therapy in pancreatic cancer.
Chun YS; Cooper HS; Cohen SJ; Konski A; Burtness B; Denlinger CS; Astsaturov I; Hall MJ; Hoffman JP
Ann Surg Oncol; 2011 Dec; 18(13):3601-7. PubMed ID: 21947697
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic carcinoma deemed unresectable at exploration may be resected for cure: an institutional experience.
Chao C; Hoffman JP; Ross EA; Torosian MH; Eisenberg BL
Am Surg; 2000 Apr; 66(4):378-85; discussion 386. PubMed ID: 10776876
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy and survival after resection of pancreatic adenocarcinoma: a population-based analysis.
Mayo SC; Austin DF; Sheppard BC; Mori M; Shipley DK; Billingsley KG
Cancer; 2010 Jun; 116(12):2932-40. PubMed ID: 20336787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
